Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434160 | 1.00 | MAPT (0.65) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL29434159 | 1.00 | MAPT (0.65) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL17204101 | 0.90 | MAPT (0.61) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL1309176 | 0.84 | MAPT (0.63) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL23299977 | 0.82 | MAPT (0.53) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL245771 | 0.82 | MAPT (0.61) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL908493 | 0.82 | MAPT (0.71) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL21464455 | 0.82 | MAPT (0.61) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL913213 | 0.82 | KMT2A (0.63) | MAPTCYP1A2CYP2D6KMT2ARAB9A | |
| SCHEMBL16121172 | 0.82 | MAPT (0.61) | MAPTCYP1A2CYP2D6KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| WO-2025137105-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-11-10 | — | — | US | disclosed |
| US-20220340543-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-10-27 | — | — | US | disclosed |
| EP-4048259-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| CN-101133053-A | Substituted pyridine derivatives | LUNDBECK & CO AS H (DK) | 2008-02-27 | — | — | CN | disclosed |
| EP-1861394-A1 | SUBSTITUTED PYRIDINE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006092143-A1 | SUBSTITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-09-08 | — | — | WO | disclosed |
| EP-1687004-A2 | PYRIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | MAPT 1165/4885CYP1A2 49/4885CYP2D6 120/4885 |
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | BRAF, MAP2K2, MAP2K1 | MAPT 204/4885CYP1A2 4363/4885CYP2D6 4621/4885 |
| US-20220340543-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-11407737-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | MAPT 1165/4885CYP1A2 49/4885CYP2D6 120/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | MAPT 3440/4885CYP1A2 4124/4885CYP2D6 4554/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.